Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

Author

TALPAZ, Moshe; SILVER, Richard T; HOCHHAUS, Andreas; OTTMANN, Oliver G; GRATWOHL, Alois; BACCARANI, Michele; STONE, Richard; TURA, Sante; MAHON, Francois-Xavier; FERNANDES-REESE, Sofia; GATHMANN, Insa; CAPDEVILLE, Renaud; DRUKER, Brian J; KANTARJIAN, Hagop M; SAWYERS, Charles L; GOLDMAN, John M; GAMBACORTI-PASSERINI, Carlo; GUILHOT, Francois; SCHIFFER, Charles A; FISCHER, Thomas; DEININGER, Michael W. N; LENNARD, Anne L
Abteilung Haematologie/Onkologie, Universität Leipzig, Leipzig, Germany
Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, United States
Dana Farber Cancer Institute, Boston, MA, United States
Department of Experimental Oncology, National Cancer Institute, Milan, Italy
Department of Haematology, Hammersmith Hospital/ICSM, London, United Kingdom
Department of Haematology, Royal Victoria Infirmary, University of Newcastle upon Tyne, United Kingdom
Department of Medicine and Molecular Biology Institute, University of California at Los Angeles, CA, United States
Department of Oncology Hematology and Cell Therapy, C.H.U de Poitiers, Poitiers, France
Division of Hematology, Oregon Health Sciences University, Portland, United States
Division of Hematology, Udine University Hospital, Udine, Italy
Division of Hematology, Universitätsklinik, Kantonspital, Basel, Switzerland
Hematology Section, San Gerardo Hospital, Monza, Italy
Instituto di Ematologia, Ospedale Policlinicl Sant'Orsola-Malpighi, Bologna, Italy
Laboratoire de Greffe de Moelle, Universite Victor Segalen, Bordeaux, France
M. D. Anderson Cancer Center, Houston, TX, United States
Medizinische Klinik III, Johan Wolfgang Goethe Universität, Frankfurt, Germany
Medizinische Universitätsklinik Mannheim der Universitat Heidelberg, Mannheim, Germany
New York-Presbyterian Hospital Weill Medical College of Cornell University, New York, NY, United States
Novartis Pharma AG, Basel, Switzerland
Universitätsklinikum, Medizinische Klinik und Poliklinik, Mainz, Germany

Source

Blood. 2002, Vol 99, Num 6, pp 1928-1937 ; ref : 41 ref

ISSN

0006-4971

Scientific domain

Medical oncology; Hematology

Publisher

The Americain Society of Hematology, Washington, DC

Publication country

United States

Document type

Article

Language

English

Keyword (fr)

Anticancéreux Chimiothérapie Chronique Efficacité traitement Essai clinique phase II Homme Inhibiteur enzyme Leucémie myéloïde Protein-tyrosine kinase Traitement Imatinib Phase d'accélération Enzyme Hémopathie maligne Myéloprolifératif syndrome Transferases

Keyword (en)

Antineoplastic agent Chemotherapy Chronic Treatment efficiency Phase II trial Human Enzyme inhibitor Chronic myelocytic leukemia Protein-tyrosine kinase Treatment Imatinib Accelerated phase Enzyme Malignant hemopathy Myeloproliferative syndrome Transferases

Keyword (es)

Anticanceroso Quimioterapia Crónico Eficacia tratamiento Ensayo clínico fase II Hombre Inhibidor enzima Leucemia mieloidea Protein-tyrosine kinase Tratamiento Enzima Hemopatía maligna Mieloproliferativo síndrome Transferases

Classification

Pascal

002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents / 002B02R02 Chemotherapy

Discipline

Pharmacological treatments

Origin

Inist-CNRS

Database

PASCAL

INIST identifier

13540625

Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS